Regulatory & Reimbursement
FDA Output, June 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in June 2026. Updated June 30.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Executive Interviews
NVIDIA's Strategy in Medical Devices
NVIDIA considers medtech, and in particular, surgery, to be a core part of its healthcare strategy. It is providing the industry with a full stack of computational powers, which enable medical device companies to offer end customers, that is, healthcare providers, a new wave of innovative products.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways’ Pick of the Week
Pathways' Pick of the Week: Shuren Joins MedTech Innovator
The former CDRH Director is joining the MedTech Innovator accelerator as an advisor. Excerpted from Pathways’ Picks June 24: Devices Selected for EU Tech Assessments, Breakthrough Pilot, and More Medtech Policy Picks.